Alnylam Stock Analysis

ALNY -  USA Stock  

USD 176.89  4.64  2.69%

The current rise in Alnylam Pharmaceuticals short term price appreciation could raise concerns from investors as the firm it trading at a share price of 176.89 on very low momentum in volume. The company management teams have successfully maneuvered the firm at convenient times to take advantage of all market conditions in May. The stock standard deviation of daily returns for 90 days investing horizon is currently 1.9. The below-average Stock volatility is a good sign for longer-term investment options and for buy-and-hold investors.
Please continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Alnylam Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Alnylam Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Alnylam stock analysis module also helps to analyze the Alnylam Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Alnylam Stock Analysis Notes

About 94.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 7.55. Alnylam Pharmaceuticals had not issued any dividends in recent years. Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1453 people. For more info on Alnylam Pharmaceuticals please contact John Maraganore at 617 551-8101 or go to www.alnylam.com.

Alnylam Pharmaceuticals Quarterly Cost of Revenue

31.06 MillionShare

Alnylam Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Alnylam Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Alnylam Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Alnylam Pharmaceuticals is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 570.94 M. Net Loss for the year was (876.35 M) with profit before overhead, payroll, taxes, and interest of 414.8 M.
Alnylam Pharmaceuticals currently holds about 1.71 B in cash with (604.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.54.
Alnylam Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Over 94.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.equities.com: Alnylam Pharmaceuticals Inc falls -0.0960 percent for June 15 - Equities.com

Alnylam Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Alnylam Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Alnylam Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report5th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End10th of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Alnylam Largest EPS Surprises

Earnings surprises can significantly impact Alnylam Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2006-07-26
2006-06-30-0.28-0.31-0.0310 
2011-11-01
2011-09-30-0.35-0.310.0411 
2009-05-07
2009-03-31-0.23-0.190.0417 
View All Earnings Estimates

Alnylam Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Alnylam Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Alnylam Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Alnylam Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
21st of May 2021
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders
View
29th of April 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
12th of April 2021
Other Events
View
11th of February 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
10th of February 2021
Unclassified Corporate Event
View
8th of February 2021
Unclassified Corporate Event
View
3rd of February 2021
Unclassified Corporate Event
View
1st of February 2021
Unclassified Corporate Event
View

Alnylam Pharmaceuticals Thematic Classifications

In addition to having Alnylam Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech IdeaBiotech
Biotechnology and pharmaceuticals production and services

Alnylam Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Alnylam Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alnylam Pharmaceuticals backward and forwards among themselves. Alnylam Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Alnylam Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Fmr LlcCommon Shares17.5 M2.5 B
Vanguard Group IncCommon Shares10.6 M1.5 B
Baillie Gifford CoCommon Shares10.1 M1.4 B
Wellington Management Group LlpCommon Shares9.1 M1.3 B
Blackrock IncCommon SharesM1.3 B
Price T Rowe Associates IncCommon Shares5.6 M787.2 M
Dodge CoxCommon Shares4.3 M610.2 M
Note, although Alnylam Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Alnylam Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 19.78 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Alnylam Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Alnylam Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Alnylam Profitablity

Alnylam Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Alnylam Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Alnylam Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Alnylam Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Alnylam Pharmaceuticals' profitability requires more research than a typical breakdown of Alnylam Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (153.49) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (140.91) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -1.41.
Last ReportedProjected for 2021
Return on Investment(62.61) (67.55) 
Return on Average Assets(0.28) (0.30) 
Return on Average Equity(0.69) (0.70) 
Return on Invested Capital(0.31) (0.33) 
Return on Sales(1.56) (1.69) 

Management Efficiency

The entity has return on total asset (ROA) of (18.17) % which means that it has lost $18.17 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (77.01) %, meaning that it created substantial loss on money invested by shareholders. Alnylam Pharmaceuticals management efficiency ratios could be used to measure how well alnylam pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -67.55 in 2021. Return on Average Assets is likely to drop to -0.3 in 2021. Alnylam Pharmaceuticals Total Assets are fairly stable at the moment as compared to the past year. Alnylam Pharmaceuticals reported Total Assets of 3.41 Billion in 2020. Current Assets is likely to rise to about 2.8 B in 2021, whereas Goodwill and Intangible Assets are likely to drop slightly above 400.8 K in 2021.
Last ReportedProjected for 2021
Book Value per Share 8.84  10.26 
Enterprise Value over EBIT(19.00) (20.50) 
Enterprise Value over EBITDA(21.43) (23.13) 
Price to Book Value 14.86  12.12 
Tangible Assets Book Value per Share 29.63  24.21 
Enterprise Value14.9 B16.1 B
Tangible Asset Value3.4 B3.7 B

Technical Drivers

As of the 19th of June, Alnylam Pharmaceuticals shows the Mean Deviation of 1.51, downside deviation of 1.85, and Risk Adjusted Performance of 0.1101. Alnylam Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Alnylam Pharmaceuticals, which can be compared to its rivals. Please confirm Alnylam Pharmaceuticals downside deviation, treynor ratio, as well as the relationship between the Treynor Ratio and expected short fall to decide if Alnylam Pharmaceuticals is priced correctly, providing market reflects its regular price of 176.89 per share. Given that Alnylam Pharmaceuticals has jensen alpha of 0.3195, we suggest you to validate Alnylam Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Alnylam Pharmaceuticals Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Alnylam Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alnylam Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alnylam Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alnylam Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Akshay Vaishnaw 3 days ago via Macroaxis 
Acquisition by Akshay Vaishnaw of 5416 shares of Alnylam Pharmaceuticals subject to Rule 16b-3
John Maraganore over a month ago via Macroaxis 
Exercise or conversion by John Maraganore of 33979 shares of Alnylam Pharmaceuticals subject to Rule 16b-3
Tanguler Tolga over three months ago via Macroaxis 
Alnylam Pharmaceuticals exotic insider transaction detected
Poulton Jeffrey V over three months ago via Macroaxis 
Acquisition by Poulton Jeffrey V of 23200 shares of Alnylam Pharmaceuticals subject to Rule 16b-3
Laurie Keating over three months ago via Macroaxis 
Acquisition by Laurie Keating of 4584 shares of Alnylam Pharmaceuticals subject to Rule 16b-3
Laurie Keating over three months ago via Macroaxis 
Exercise or conversion by Laurie Keating of 6000 shares of Alnylam Pharmaceuticals subject to Rule 16b-3
Laurie Keating over three months ago via Macroaxis 
Exercise or conversion by Laurie Keating of 13000 shares of Alnylam Pharmaceuticals subject to Rule 16b-3
Steven Paul over three months ago via Macroaxis 
Exercise or conversion by Steven Paul of 15000 shares of Alnylam Pharmaceuticals subject to Rule 16b-3
Phillip Sharp over six months ago via Macroaxis 
Exercise or conversion by Phillip Sharp of 30000 shares of Alnylam Pharmaceuticals subject to Rule 16b-3
John Maraganore over six months ago via Macroaxis 
Exercise or conversion by John Maraganore of 34765 shares of Alnylam Pharmaceuticals subject to Rule 16b-3
Barry Greene over six months ago via Macroaxis 
Exercise or conversion by Barry Greene of 44530 shares of Alnylam Pharmaceuticals subject to Rule 16b-3
John Maraganore over six months ago via Macroaxis 
Exercise or conversion by John Maraganore of 34765 shares of Alnylam Pharmaceuticals subject to Rule 16b-3

Alnylam Pharmaceuticals Technical and Predictive Indicators

Alnylam Pharmaceuticals Forecast Models

Alnylam Pharmaceuticals time-series forecasting models is one of many Alnylam Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Alnylam Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Alnylam Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Alnylam Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Alnylam shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Alnylam Pharmaceuticals. By using and applying Alnylam Stock analysis, traders can create a robust methodology for identifying Alnylam entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin(76.18) (82.19) 
EBITDA Margin(1.41) (1.52) 
Gross Margin 0.84  0.85 
Profit Margin(1.74) (1.88) 
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1453 people.

Current Alnylam Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Alnylam analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Alnylam analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
178.72Buy18Odds
Alnylam Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Alnylam analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Alnylam stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Alnylam Pharmaceuticals, talking to its executives and customers, or listening to Alnylam conference calls.
Alnylam Analyst Advice Details

Alnylam Stock Analysis Indicators

Alnylam Pharmaceuticals stock analysis indicators help investors evaluate how Alnylam Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Alnylam Pharmaceuticals shares will generate the highest return on investment. By understating and applying Alnylam Pharmaceuticals stock analysis, traders can identify Alnylam Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio4.69
Fifty Two Week Low119.29
Revenue Growth78.50%
Shares Short Prior Month3.72M
Average Daily Volume Last 10 Day667.8k
Average Daily Volume In Three Month502.53k
Shares Percent Shares Out3.50%
Gross Margins83.22%
Short Percent Of Float4.08%
Forward Price Earnings-47.28
Float Shares116.84M
Fifty Two Week High178.41
Enterprise Value To Ebitda-18.67
Fifty Day Average140.77
Two Hundred Day Average143.49
Enterprise Value To Revenue25.00
Please continue to Trending Equities. Note that the Alnylam Pharmaceuticals information on this page should be used as a complementary analysis to other Alnylam Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Alnylam Pharmaceuticals Stock analysis

When running Alnylam Pharmaceuticals price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Alnylam Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.